Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 12Terminated 3Unknown 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 49Lymphoma, Large B-Cell, Diffuse 15Lymphoma, Follicular 14Lymphoma, B-Cell, Marginal Zone 13Lymphoma 8Recurrence 7Neoplasms 6Lymphoma, Non-Hodgkin 6Lymphoma, Mantle-Cell 5Lymphoma, B-Cell 4Neoplasms, Plasma Cell 3Neoplasm, Residual 3Lymphoma, T-Cell, Peripheral 3Smoldering Multiple Myeloma 2Leukemia, Plasma Cell 2Hematologic Neoplasms 2Waldenstrom Macroglobulinemia 1Vitamin D Deficiency 1Peripheral Nervous System Diseases 1Paraproteinemias 1Leukemia, Myeloid, Acute 1Leukemia, Hairy Cell 1Hodgkin Disease 1Hematologic Diseases 1Heart Failure 1Dendritic Cell Sarcoma, Interdigitating 1Corneal Diseases 1Cardiotoxicity 1Burkitt Lymphoma 1Blood Protein Disorders 1

Interventions

Cyclophosphamide 13pembrolizumab 8Brentuximab Vedotin 8fludarabine 7Nivolumab 7Whole-Body Irradiation 6Specimen Handling 6Mycophenolic Acid 6Gemcitabine 6Etoposide 6Doxorubicin 6Dacarbazine 6fludarabine phosphate 5Vinblastine 5Melphalan 5Granulocyte Colony-Stimulating Factor 5Filgrastim 5Dexamethasone 5Stem Cell Transplantation 4Cytarabine 4Vinorelbine 3Tacrolimus 3Magnetic Resonance Spectroscopy 3Cyclosporine 3Carmustine 3Blood Specimen Collection 3thymoglobulin 2polatuzumab vedotin 2pegylated granulocyte colony-stimulating factor 2pegfilgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Hodgkin Disease × Lenalidomide × Clear all
NCT05615636 2026-05-20

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

M.D. Anderson Cancer Center

Phase 2 Recruiting
36 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡